Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Pharma Pricing Analysis - Sutent vs. Nexavar Sales Revenue

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
676 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Mar 24, 2011

This pharma pricing video compares Sutent and Nexavar sales, quarterly, over the last 4 years and analyses market access opportunities. Specifically, we focus on the implications of heptacellular carcinoma (HCC) approval in Nexavar.

Learn more at http://pharmapricing.org/about-me-2

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more